Minimally Invasive Fully Endoscopic Mitral Valve Repair After Failed M-TEER is a Valid Treatment Option for Many Patients

Saturday, March 8, 2025

10:36 AM – 10:44 AM ET

Speaker(s)

Hendrik Treede, MD

Director
University Heart and Vascular Center Mainz
Mainz, Rheinland-Pfalz, Germany

Disclosure(s): Edwards Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); JenaValve Technology Inc.: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); medtronic.: Consultant (Ongoing), Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); TriCares: Consultant (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Disclosure(s):

Hendrik Treede, MD: Edwards Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); JenaValve Technology Inc.: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); medtronic.: Consultant (Ongoing), Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); TriCares: Consultant (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)